Bioatla investor relations
WebThe Investor Relations website contains information about BioAtla, Inc's business for stockholders, potential investors, and financial analysts. WebMar 25, 2024 · Net loss for the full year ended December 31, 2024 was $35.9 million compared to a net loss of $29.8 million for the year 2024. About BioAtla, Inc. BioAtla is a global clinical-stage biotechnology ...
Bioatla investor relations
Did you know?
WebNov 17, 2024 · Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It looks like hedge funds own 12% of BioAtla shares. WebEdit. BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.
WebNov 13, 2024 · BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, filed on Friday with the SEC to raise up to $100 million in an initial public … WebNov 4, 2024 · BioAtla intends to use the net proceeds to be received by it in the offering, along with its existing cash and cash equivalents to fund our research and development …
WebApr 16, 2024 · About BioAtla, LLC. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and Beijing, China. BioAtla develops novel monoclonal antibody and other ... WebMay 4, 2024 · First Quarter Financial Results. Cash and cash equivalents as of March 31, 2024 were $219.4 million, compared to $245.0 million as of December 31, 2024. We …
WebThe generative AI drug company ramps up its internal pipeline and R&D portfolio, tapping into European markets, talent, and tech VANCOUVER, Wash. and NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced its expansion. 21 Feb / 23.
WebApr 3, 2024 · Investor FAQs; Email Alerts; Contact IR; SEC Filings Group. Filing year. Items per page. Filing date Form Description Filing Group View; 04/03/23: 4: Statement of changes in beneficial ownership of securities. 3,4,5. 0001209191-23-022427.pdf. 0001209191-23-022427.rtf ... BioAtla ® is a leading San ... bing refresh buttonWebFeb 27, 2024 · The Investor Relations website contains information about BioAtla, Inc's business for stockholders, potential investors, and financial analysts. Skip to main … Investor FAQs; Email Alerts; Contact IR; News Releases Year. Date ; 3/23/23 … Investor FAQs; Email Alerts; Contact IR; Events and Presentations Past Events. … Investor FAQs; Email Alerts; Contact IR; SEC Filings Group. Filing year. Items … d6 they\\u0027llWebDec 15, 2024 · BioAtla is registered under the ticker NASDAQ:BCAB . Their stock opened with $18.00 in its Dec 15, 2024 IPO. BioAtla is funded by 20 investors. Vivo Capital and Acuta Capital Partners are the most recent investors. BioAtla has a post-money valuation in the range of $500M to $1B as of Jul 16, 2024, according to PrivCo. d6 thicket\\u0027sWebDec 15, 2024 · BioAtla is registered under the ticker NASDAQ:BCAB . Their stock opened with $18.00 in its Dec 15, 2024 IPO. BioAtla is funded by 20 investors. Vivo Capital and … d6 they\\u0027veWebDec 16, 2024 · In addition, BioAtla has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the initial public offering price, less underwriting discounts ... d6 thermostat\\u0027sWebMar 24, 2024 · BioAtla, Inc. (NASDAQ:NASDAQ:BCAB) Q4 2024 Earnings Call Transcript March 23, 2024 4:30 PM ETCompany ParticipantsBruce Mackle - Investor Relations, … d6 they\\u0027reWebDec 9, 2024 · BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $150 million by offering ... d6 they\u0027ve